Companies

NovaBay Pharmaceuticals Inc. is a publicly traded company (AMEX) located in the San Francisco Bay Area. NovaBay was founded in 2000 with IPO in 2007. We currently have approximately 28 employees, primarily in Research and Development. NovaBay is a clinical stage company developing a first-in-class, anti-infective platform of compounds, called the Aganocide compounds, for the treatment or prevention of a wide range of infections in hospital and non-hospital environments. Many of these infections have become increasingly difficult to treat because of the rapid rise in drug resistance. We have discovered and are developing a class of non-antibiotic anti-infective compounds, which we have named Aganocide compounds. These compounds are based upon small molecules that are naturally generated by white blood cells when defending the body against invading pathogens. We believe that our Aganocide compounds could form a platform on which to create a variety of products to address differing needs in the treatment and prevention of bacterial and viral infections. In laboratory testing, our Aganocide compounds have demonstrated the ability to destroy all bacteria against which they have been tested. Furthermore, because of their mechanism of action, we believe that bacteria are unlikely to develop resistance to our Aganocide compounds.

NovaBay's anti-infective platform of compounds called the Aganocide compounds® have demonstrated in laboratory tests equivalent activity to the active antimicrobial molecules generated within white blood cells. The Aganocide compounds are being developed for the topical treatment and prevention of a wide variety of topical infections, including those that are antibiotic resistant. NVC-422 our lead Aganocide compound has show clinical proof of concept with a topical gel in a 127 patient phase 2 clinical study in impetigo (skin infection), with a catheter irrigation solution in proof of concept study in UCBE (urinary catheter blockage and encturstation) and in a proof of concept study with an ophthalmic solution for treatment of viral conjunctivitis.

In laboratories, these Aganocide® compounds have demonstrated equivalent activity to the active antimicrobial molecules generated within white blood cells. The Aganocide compounds are being developed for the topical treatment and prevention of a wide variety of topical infections, including those that are antibiotic resistant.

NovaBay is seeking partners for:
- NVC-422 urinary catheter irrigation solution for UCBE (urinary catheter blockage and encrustation).
- NVC-422 ophthalmic eye drop for the treatment of viral conjunctivitis
- NeutroPhase wound cleanser solution: NovaBay is seeking distributors around the world to market NeutroPhase our FDA 510(k) cleared wound cleanser. We expect to be in commercial production in early 2012.

NovaBay is developing commercial opportunities for its portfolio of anti-infective Aganocide compounds in four distinct healthcare markets: dermatology, ophthalmology, urology and hospital infections. Each of these market segments are underserved by current products and therefore the opportunity exists for improved treatments. NovaBay's strategy is to address these market opportunities either through partnerships and collaborations for later stage clinical development and/or commercialization. Depending on the products we may seek a global partner or retain commercial rights in the US and will seek partnerships for the rest of the world.